Tarsier Pharma Appoints Emilee Fulcher as VP of Clinical Affairs

TEL-AVIV, Israel—May 28, 2024—Tarsier Pharma, Ltd, a biopharmaceutical company innovating in the field of ophthalmology, has announced the new appointment of Emilee Fulcher as Vice President of Clinical Affairs. Tarsier Pharma, currently in the late stages of developing new treatments for blinding ocular diseases, is focused on advancing its therapies for conditions that severely impact vision.

In her new role, Fulcher will oversee the TRS01 and TRS02 clinical programs, which are integral to the company's development pipeline for Dazdotuftide (TRS). Dazdotuftide is a cutting-edge, multi-target drug designed for treating ocular diseases. It is being developed in two forms: an eye drop formulation (TRS01) and a slow-release biodegradable intravitreal injection (TRS02).

The CEO of Tarsier, Daphne Haim-Langford, expressed enthusiasm about Fulcher's appointment. "We are thrilled to welcome Emilee to the Tarsier team. Her leadership and extensive experience in ophthalmic research make her the ideal person to lead our clinical development efforts. She is not only professional and knowledgeable but also deeply compassionate and aligned with our vision to save sight, making her an invaluable asset to the team," said Haim-Langford.

Fulcher brings with her 20 years of experience in the pharmaceutical industry, with a focus on ophthalmology clinical trials. Before joining Tarsier, she was among the initial employees at Lexitas, a CRO specializing in ophthalmic research. During her 11-year career at Lexitas, Fulcher successfully led trials in various ophthalmic conditions and phases, including all three TRS01 clinical trials completed so far. She also has experience from her tenure at UCB Biosciences and Inspire Pharmaceuticals, where she held positions in preclinical drug development and clinical operations.

Expressing her enthusiasm about the new role, Fulcher stated, "I am deeply honored to join the talented team at Tarsier and eager to leverage my expertise to bring our innovative treatments to patients. I am passionate about Tarsier's mission and excited to advance our clinical programs. These programs have the potential to transform the treatment landscape for patients with debilitating and blinding conditions, including uveitis and specifically uveitic glaucoma. As we prepare to initiate the Tarsier-04 Phase 3 trial, we are well-positioned to build on the momentum of our recently completed TRS4Vision Phase 3 trial, which highlighted TRS01's potential as an effective and safe treatment for uveitis."

Tarsier Pharma is optimistic about the future under Fulcher's leadership and looks forward to her contributions in driving the company's clinical development initiatives.